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Mu ltip l e  s c l ero s i s  ( M S )  i s a n  a u t o i m m u n e - m e d i a t e d demyelinating disease of the central nervous system (CNS). The disease 
has four clinical forms: relapsing-remitting (RRMS), 
progressive relapsing (PRMS), primary progressive 
(PPMS), and secondary progressive (SPMS).1
Autoreactive pathogenic helper T cells (Th) 
play a prominent role in the pathogenesis of MS. 
Experimental autoimmune encephalomyelitis (EAE) 
is the most frequently used animal model system for 
studying MS.2 Upon antigenic stimulation, naïve Th 
cells are activated and undergo several proliferations 
before finally differentiating into several subsets (i.e., 
Th1, Th2, Th17) and regulatory T cells (Treg), which 
are characterized by the production of particular 
cytokine profiles. Th1 cells that release inflammatory 
cytokines (e.g., interferon (IFN)-γ, tumor necrosis 
factor (TNF)-α) as well as Th17 cells that secrete 
interleukin (IL)–17 play central role in the 
pathogenesis of MS and EAE diseases.3 Treg cells, 
which secrete transforming growth factor (TFG)-β, 
and Th2 cells, which release IL–4, were thought to 
be important in diseases amelioration.4 Macrophages 
may also play a pivotal role in the pathogenesis of 
MS and EAE diseases.5 In our previous studies, 
higher levels of a Th17–related chemokine (CCL20) 
and lower levels of a Th2/Treg-related chemokine 
(CCL22) were observed in patients with MS.6,7
IL–33 is a new member of the IL–1 family. The 
IL–33 receptor is a heterodimer comprised of ST2L 
(or ST2) and IL–1R accessory protein (IL–1RAcP). 
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A B S T R AC T
Objectives: Interleukin (IL)–33 is a cytokine with both pro- and anti-inflammatory 
effects involved in the pathogenesis of some inflammatory diseases. The purpose of 
this investigation was to evaluate the serum and cerebrospinal fluid (CSF) IL–33 
concentrations in patients with multiple sclerosis (MS). Methods: Blood specimens were 
obtained from 140 patients with MS (46 males and 94 females) with various disease 
patterns and treatment plans and 140 healthy subjects (47 males and 93 females), who acted 
as a control group. CSF samples were collected from 20 MS group and 20 sex- and age-
matched patients with other neurological diseases of nonautoimmune etiology. The serum 
and CSF concentrations of IL–33 were measured by the enzyme-linked immunosorbent 
assay. Results: The serum and CSF IL–33 levels were significantly higher in the MS group 
compared to the control group (p<0.001 and p<0.050, respectively). The serum IL–33 
concentrations were also significantly higher in newly diagnosed (untreated) patients and 
patients treated with methylprednisolone or with interferon-β and methylprednisolone 
compared to the healthy patient group (p<0.007, p<0.002, and p<0.010, respectively). 
Moreover, the serum IL–33 concentrations in patients with relapsing-remitting (RRMS), 
primary progressive (PPMS), and secondary progressive (SPMS) forms of the disease were 
significantly higher than in the healthy control group (p<0.006, p<0.001, and p<0.020, 
respectively). Conclusions: Our results showed increased concentrations of IL–33 in 
patients with MS including both untreated and treated MS patients and patients with 
the RRMS, SPMS, and PPMS forms. This suggests that IL–33 may be involved in the 
pathogenesis of all MS forms and treatment with methylprednisolone or both interferon-β 
plus methylprednisolone has no influence on IL–33 concentrations.
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ST2 is expressed on some leukocytes particularly on 
mast cells and activated Th2 cells. It acts to increase 
the effector function of these cells.8 The binding of 
IL–33 to its receptor induces the secretion of pro-
inflammatory cytokines from mast cells and Th2 
lymphocytes,8 stimulates the migration of Th2 cells,9 
promotes the activation of the eosinophil, basophil, 
and natural killer (NK) cells,10 potentiates the 
Th1- and Th2–related immune responses,11 triggers 
IFN-γ secretion by invariant NK T cells (iNKT) 
and NK cells, and increases the count of iNKT cells 
in the spleen.12 The importance of IL–33 has been 
suggested in the strengthening of innate immunity 
and may act as an alarmin to activate the immune 
system following cell necrosis or apoptosis.13
IL–33 is a nuclear cytokine that constitutively 
expresses in endothelial and epithelial cells.13 
Interestingly, the highest quantity of IL–33 
expression in mice was found in the brain and spinal 
cord,14 suggesting the possible specific actions of IL–
33 in the CNS additional to its role in the immune 
system. Recent investigations have also demonstrated 
that IL–33 may contribute to the pathogenesis of 
some inflammatory diseases suggesting that IL–33 
may have strong pro-inflammatory characteristics.13,15 
Although, there are a few studies regarding the 
association of IL–33 and MS, the influences of 
gender, MS patterns, and treatment program on 
IL–33 concentration have not been investigated. In 
this study, we sought to evaluate the concentration 
of IL–33 in MS patients and any association with 
gender, treatment programs, and disease patterns.
M ET H O D S
Peripheral blood specimens were collected from 
two groups between January 2013 and February 
2014. Group one was comprised of 140 patients 
with MS (46 men and 94 women) who were 
referred to the Shephah Hospital of Kerman (a city 
in southeast Iran). MS was diagnosed by specialist 
neurologists, according to the Mcdonald’s criteria.16 
Of the 140 patients, 102 patients presented with 
RRMS, 28 with SPMS, eight with PPMS, and two 
with PRMS. The patients were also differentiated 
as newly (n = 51) and previously diagnosed 
(n = 89). Newly diagnosed patients were enrolled 
into the study before receiving any treatment. 
Previously diagnosed patients were treated with 
methylprednisolone, IFN-β, or IFN-β plus 
methylprednisolone. The treated MS patients 
received intravenous methylprednisolone 1000 mg/
day for three to five days following an acute MS 
attack or 30 μg intramuscular IFN-β once weekly 
(Avonex, Biogen, Massachusetts, US or CinnoVex, 
CinnoGen, Iran) or 44 μg subcutaneously, three 
times weekly (Rebif, Merck Serono, Switzerland) 
for at least three months. Some MS patients were 
initially treated with IFN-β (during the silent stage 
of disease) and after the occurrence of an acute MS 
attack with methylprednisolone.
Cerebrospinal fluid (CSF) samples were obtained 
from another 20 patients with MS (four men and 
16 women) and 20 sex- and age-matched patients 
(five men and 15 women) with other neurological 
diseases of nonautoimmune etiology (such as a 
tension headache or meningitis). The CSF samples 
were obtained during routine diagnostic work-
up or for other clinical purposes. CSF specimens 
were collected from patients who were not under 
immunosuppressive medication and were stored at 
–70 °C.
Group two (considered the control group) 
comprised of 140 healthy subjects (47 men and 93 
women) that were recruited among blood donors of 
the Kerman Transfusion Organization. All control 
subjects were in basic good health, with no history of 
CNS disease or any other relevant disorders. Those 
with a history of recurrent infections, asthma, allergy, 
and atopic diseases, any suspected immunological 
disorders, malignancy, surgery, smoking, drug 
use, and major trauma within six months before 
blood sampling were all excluded from the study. 
A peripheral blood specimen was taken from all 
subjects, and the sera were separated and stored at 
–70 °C.
Our study was evaluated and approved by 
the Ethical Committee of Kerman University of 
Medical Sciences. All participants gave their written 
informed consent before enrollment.
The serum and CSF IL–33 concentrations 
were determined using commercial enzyme-linked 
immunosorbent assay (ELISA) kits (BosterBio, 
California, US) according to the manufacturer’s 
instruction. The sensitivity of the test was less than 
10 pg/ml.
The Student’s t-test, analysis of variance 
(ANOVA), and chi-square tests were performed 
for comparison of variables between groups. The 
data were analyzed by SPSS Statistics (Chicago, 
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Illinois, US) version 18. A p-value less than 0.050 
was considered statistically significant.
R E S U LTS
The mean age of patients with MS was 35.0±8.3 
years and 36.1±8.1 years in the control group. There 
were 94 (67.1%) female patients with MS and 46 
(32.9%) males. In the control group, there were 93 
(66.4%) females and 47 (33.6%) males. There was 
no significant difference between the MS group 
and control group in age and gender distribution 
(p = 0.260 and p = 0.500, respectively).
CSF samples were obtained from 20 patients with 
MS and 20 age- and sex-matched control patients. The 
mean age was 33.6±9.3 years in the MS group and 
35.3±7.0 years in the control group. There were 16 
(80.0%) female and four (20.0%) male patients with 
MS and 15 (75.0%) female and five (20.0%) males in 
the control group. There was no significant difference 
between the patients with MS and the control group 
in mean age and gender distribution (p = 0.430 and 
 p = 0.700, respectively).
The mean serum IL–33 concentration was 
408.0±55.3 pg/ml in the MS group and 156.8±35.4 
pg/ml in the control group. The serum IL–33 
concentration was significantly higher in the MS 
group compared to the control group (p<0.001) 
[Table 1]. In the control group, the difference in 
the serum IL–33 concentrations between males 
and females was not significant. However, cytokine 
levels were found to be higher in females. In female 
MS patients, the serum IL–33 concentrations were 
significantly higher compared to male patients 
(p<0.050). In both male and female patients 
with MS, the serum IL–33 concentrations were 
significantly higher compared to patients in the 
control group of the same gender (p<0.050 and 
p<0.010, respectively) [Table 1].
The mean CSF concentrations of IL–33 were 
76.6±12.3 pg/ml in the MS group and 44.0±6.4 pg/
ml in the control group. The CSF concentrations of 
IL–33 were significantly higher in the MS group than 
in the control group (p<0.050) [Table 2]. In the MS 
and control group, the difference in the mean CSF 
concentrations of IL–33 between men and women 
were not significant. In female patients with MS, 
the CSF concentrations of IL–33 were significantly 
higher compared to the control group (p<0.040). In 
males, this difference was not significant [Table 2].
Serum IL–33 concentrations in newly diagnosed 
(untreated) and previously diagnosed (treated) MS 
patients are given in Table 3. Overall, the serum IL–
33 concentrations in untreated and treated patients 
were significantly higher than the control group 
(p<0.007 and p<0.001, respectively). However, there 
was no significant difference between untreated 
and treated patients. In both untreated and treated 
Table 1: Serum levels of IL–33 in patients with MS 
patients and the control group according to gender.
Group Sex Number IL–33 levels* p-value
MS Male 46 268.8±67.5 0.050
Female 94 492.2±77.6
Total 140 408.0±55.3
Control Male 47 121.2±25.7 0.310
Female 93 192.3±65.9
Total 140 156.8±35.4
*Values expressed as mean±SD. The serum levels of cytokine are expressed as pg/ml. 
IL–33: interleukin–33; MS: multiple sclerosis; SD: standard deviation.
Table 2: CSF levels of IL–33 in MS patients and 
control group according to gender.
Group Sex Number IL–33 levels* p-value
MS Male 4 66.6±37.0 0.700
Female 16 79.1±13.0
Total 20 76.6±12.3
Matched 
controls
Male 5 38.4±7.3 0.500
Female 15 45.9±8.2
Total 20 44.1±6.4
*Values expressed as mean±SD. The CSF levels of cytokine expressed as pg/ml. 
CSF: cerebrospinal fluid; IL–33: interleukin–33; MS: multiple sclerosis; 
SD: standard deviation.
Table 3: Serum levels of IL–33 in newly (untreated) 
and previously diagnosed (treated) patients with MS 
according to gender.
Group Sex Number IL–33 
levels*
p- value
Untreated Male 25 289.3±83.1 0.320
Female 26 452.4±140.9
Total 51 372.4±82.6
Treated Male 21 244.4±112.1 0.100
Female 68 512.8±93.3
Total 89 433.4±628.9
Control Male 47 121.2±25.7 0.310
Female 93 192.3±65.9
Total 140 156.7±35.4
*Values expressed as mean±SD. The serum levels of cytokine expressed as pg/ml. 
IL–33: interleukin–33; MS: multiple sclerosis; SD: standard deviation.
42 A b d o ll a h  Ja fa r z a d eh ,  et  a l .
O M A N  M E d  J,  V O L  3 1 ,  N O  1 ,  JA N UA Ry  2 0 1 6
43A b d o ll a h  Ja fa r z a d eh ,  et  a l .
patients, no significant differences were observed 
between males and females concerning the IL–33 
concentrations [Table 3].
The serum IL–33 concentrations in treated 
MS patients with methylprednisolone or both of 
IFN-β plus methylprednisolone were significantly 
higher than the control group (p<0.002 and p<0.01, 
respectively). However, no significant difference 
was observed in patients treated with IFN-β and the 
control group. The serum IL–33 concentrations in 
patients treated with IFN-β was lower compared 
to untreated patients, but the difference was not 
significant [Table 4 and Table 5]. No significant 
differences were observed in the mean serum 
levels of IL–33 between patients treated with 
methylprednisolone, IFN-β, or both IFN-β plus 
methylprednisolone [Table 5].
No significant differences in serum IL–33 
concentration were observed between patients with 
various MS patterns. However, the serum IL–33 
concentrations in patients with RRMS, SPMS, and 
PPMS were significantly higher than the control 
group (p<0.006, p<0.001, and p<0.020, respectively) 
[Table 6].
D I S C U S S I O N
We observed increased concentrations of IL–33 in 
both serum and CSF samples from patients with 
MS, which suggests that IL–33 contributes to its 
pathogenesis. In both male and female patients 
with MS, the serum IL–33 concentrations were 
significantly higher compared to the control group 
subjects with the same gender. Accordingly, the 
elevated IL–33 concentrations may contribute to 
the pathogenesis of MS in both genders.
In female patients with MS disease, the mean 
CSF IL–33 concentration was also significantly 
higher compared to women in the control group. 
In male patients with MS disease, the mean CSF 
IL–33 concentration was also higher compared to 
men in the control group, but the difference was not 
statistically significant. This was probably due to a 
low sample size of men. The use of a suitable sample 
size of CSF from men in any future studies could 
clarify this association. Recent investigations have 
also indicated that IL–33 may be involved in the 
pathogenesis of chronic inflammatory diseases such 
as asthma, rheumatoid arthritis, and anaphylaxis 
suggesting that IL–33 may have potent pro-
inflammatory characteristics.13,17
Attention has been focused on the role of IL–
33 in the pathogenesis of immune-mediated CNS 
diseases due to very high levels of IL–33 mRNA 
expression in the brain and spinal cord.14 The IL–
33 is produced by some cells such as keratinocytes, 
dendritic cells, activated macrophages, endothelial 
cells, epithelial cells, smooth muscle cells, and 
fibroblasts.18 Furthermore, IL–33 is mainly produced 
Table 4: Serum levels of cytokine IL–33 in MS 
patients according to treatment.
Group Treatment Number IL–33 
levels*
p-value
MS IFN-β 6 285.1±153.0 0.620
MP 16 511.8±187.6
IFN-
β+MP
65 426.0±88.2
No 
treatment
51 372.5±82.6
Control - 140 156.8±35.4
*Values expressed as mean±SD. The serum levels of cytokine expressed as pg/ml. 
IL–33: interleukin–33; MS: multiple sclerosis; SD: standard deviation; 
IFN-β: interferon-β; MP: methylprednisolone
Table 5: Statistical comparison of the serum IL–33 
levels in patients with MS patients, according to 
their treatment program.
Treatment IFN-β MP IFN-β 
+MP
No 
treatment
IFN-β - 0.492 0.446 0.725
MP 0.492 - 0.649 0.443
IFN-β+MP 0.446 0.649 - 0.658
No treatment 0.725 0.443 0.658 -
Control 0.346 0.002 0.006 0.007
IFN-β: interferon-β; MP: methylprednisolone
Table 6: Serum levels of IL–33 in MS patients 
according to disease patterns.
Group Diseases
form
Number IL–33 levels* p-value
MS RRMS 102 364.1±61.3 0.530
SPMS 28 567.2±155.3
PPMS 8 486.6±127.51
PRMS 2 374.6±375.1
Total 140 408.0±55.3
Control - 140 156.7±35.4
*Values expressed as mean±SD. The serum levels of cytokine expressed as pg/ml. 
IL–33: interleukin–33; MS: multiple sclerosis; SD: standard deviation; 
PPMS: primary progressive multiple sclerosis; PRMS: progressive-relapsing 
multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SPMS: 
secondary progressive multiple sclerosis.
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by astrocytes in murine spinal cord19 and human 
CNS tissues.20 This suggests that IL–33–producing 
astrocytes may contribute to innate immune 
responses in the CNS. Astrocytes also express the 
IL–33 receptor, and IL–33 expression by astrocytes 
was increased in response to inflammatory stimuli 
and toll-like receptor ligation.21 IL–33 levels were 
elevated in the periphery and CNS of MS patients, 
indicating that IL–33 may participate in the 
pathogenesis of MS disease.20
Higher expression of IL–33 mRNA in the 
CNS of EAE mice has been observe.22 Within the 
CNS, microglia cells are the main target of IL–33, 
which induces microglia proliferation, phagocytosis, 
and the secretion of inflammatory cytokines and 
chemokines.19 IL–33 induces the synthesis of IL–6, 
IL–13, and monocyte chemoattractant protein 
(MCP)–1 in microglia, and this induction is increased 
by IL–33–activated mast cells.21 The activated 
microglia cells have been introduced as important 
effector cells that contribute to the demyelination 
process in MS.23 IL–33 is also a potent endothelial 
activator that increases endothelial permeability in 
vitro and induces vascular leakage in mouse skin.24 As 
the breakdown of the blood-brain barrier (BBB) is an 
essential step for the subsequent CNS inflammation, 
IL–33 may contribute to MS and EAE inflammation 
by disrupting the BBB in addition to modulating 
the immune system. Importantly, IL–33 may also 
facilitate recruitment of leukocytes into the CNS.25
Our results showed no significant differences 
in IL–33 serum levels between untreated patients 
and treated patients with methylprednisolone or 
both IFN-β plus methylprednisolone. The serum 
IL–33 concentrations in MS patients treated with 
methylprednisolone or both interferon-β plus 
methylprednisolone were significantly higher than 
the control group. However, there was no significant 
difference between patients treated with IFN-β and the 
control group on serum IL–33 concentrations. These 
findings indicate that treatment with IFN-β is more 
effective than treatment with methylprednisolone or 
both of IFN-β plus methylprednisolone in reducing 
serum IL–33 concentrations. Accordingly, the 
immunomodulatory effects of IFN-β may perform, 
in part, through the suppression of the IL–33 
production. In agreement with our results, it has also 
been reported that treatment with IFN-β decreases 
IL–33 expression in the plasma and peripheral 
blood mononuclear cells of patients with MS.20 In 
the absence of methylprednisolone, treatment with 
IFN-β may have reducing effects on the IL–33 levels 
whereas, in the presence of methylprednisolone, the 
IFN-β effects on IL–33 levels disappeared. Therefore, 
methylprednisolone may influence the IFN-β effects 
on IL–33 levels. The insignificant change in IL–33 
levels observed between treated and untreated MS 
patients seems to indicate that this cytokine may not 
be associated with the immunomodulatory effect of 
methylprednisolone in MS. Moreover, it should be 
noted that the immunotherapeutic effects of IFN-β 
and methylprednisolone on the MS disease may 
be performed through their modulating effects on 
the other inflammatory and immunopathological 
parameters. Our results encourage further 
studies to investigate the influences of IFN-β and 
methylprednisolone on the IL–33 production.
IL–33 may be involved in the pathogenesis 
of all MS forms. We saw higher levels of IL–33 in 
patients with RRMS, SPMS, and PPMS forms of 
MS compared to the control group. The levels of 
IL–33 were also higher in patients with PRMS, but 
valid statistical analyzes require bigger sample size 
for this MS disease pattern.
Although high expression of IL–33 mRNA in the 
CNS of mice was also demonstrated,14 studies of its 
role in the development of EAE as an animal model 
of MS are controversial.26 IL–33 may have a preventive 
role in EAE at the initial (inducible) stage of the 
disease. However, after the establishment of EAE, it 
may have an enhancing role in the disease development 
due to the presence of some inflammatory cells 
in CNS. It has been reported that IL–33 induces 
both Th1- and Th2–related immune responses 
depending on the presence of certain conditions (i.e., 
the cytokine environment and cellular types).27 For 
example, IL–33 has synergistic effects with IL–1 and 
IL–18 to increasing Th1/Th17–related response in 
experimental arthritis.28 It has been also demonstrated 
that IL–33 stimulates IFN-γ synthesis by iNKT and 
NK cells.26 IL–33 also reinforces Th1/Th17–related 
immune responses in some experimental models 
of immune disorders.29 In IL–33–treated mice, the 
antigen-stimulated draining lymph nodes produce 
more IL–17 and IFN-γ.14 Accordingly, IL–33 may 
be involved in the pathogenesis of the EAE and MS 
through the reinforcement of Th17 and Th1 cell 
functions.
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C O N C LU S I O N
Our study showed increased concentrations of IL–33 
in patients with MS. This included both untreated and 
treated patients, and those with RRMS, SPMS, and 
PPMS form of the disease. Accordingly, IL–33 may 
be involved in the pathogenesis of all MS forms, and 
treatment of MS patients with methylprednisolone 
or both IFN-β plus methylprednisolone have no 
influence on IL–33 concentrations.
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